Jim Simons Immix Biopharma, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$1.81 - $3.06 $200,575 - $339,093	-110,815 Reduced 41.74%	154,685 $306,000
Q1 2024 May 13, 2024	BUY	$2.64 - $6.68 $615,384 - $1.56 Million	233,100 Added 719.44%	265,500 $815,000
Q4 2023 Feb 13, 2024	BUY	$2.82 - $7.27 $91,368 - $235,548	32,400 New	32,400 $224,000
Q2 2023 Aug 11, 2023	BUY	$1.6 - $2.9 $16,960 - $30,740	10,600 New	10,600 $29,000
Q3 2022 Nov 14, 2022	BUY	$1.36 - $3.05 $36,788 - $82,502	27,050 New	27,050 $37,000
Q2 2022 Aug 12, 2022	SELL	$1.3 - $2.97 $81,380 - $185,922	-62,600 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.86 - $6.75 $116,436 - $422,550	62,600 New	62,600 $151,000

4.53M

8.9K

1.2K

Ticker IMMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,910,100
Market Cap $30.2M
Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.